Your session is about to expire
← Back to Search
Short Chain Fatty Acid
Butyrate Therapy for Pediatric Ulcerative Colitis
Phase 1
Recruiting
Led By Sonia Michail, MD
Research Sponsored by Children's Hospital Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients aged 7-21 years with mild to moderate ulcerative colitis
Be younger than 65 years old
Must not have
History of infectious colitis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether a therapy involving butyrate, a metabolite produced by the gut microbiome, is effective in treating ulcerative colitis in children.
Who is the study for?
This trial is for children and young adults aged 7-21 with mild to moderate ulcerative colitis. Participants must not be pregnant, should not have received ulcerative colitis therapy within the last 4 weeks, and must not have infectious colitis.
What is being tested?
The study is testing butyrate enemas as a treatment for pediatric ulcerative colitis. Butyrate is a compound produced in the gut that may help manage this condition. The trial aims to assess how effective this approach could be.
What are the potential side effects?
While specific side effects are not listed, butyrate treatments might cause discomfort or irritation at the site of enema application, digestive issues like bloating or gas, and potential changes in bowel movements.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 7 and 21 years old with mild to moderate ulcerative colitis.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had infectious colitis in the past.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
remission of clinical disease
Secondary study objectives
improvement of inflammatory markers including ESR, CRP, Calprotectin
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: open label intervention armExperimental Treatment1 Intervention
Butyrate enemas will be administered once daily for twelve weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Butyric Acid
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Children's Hospital Los AngelesLead Sponsor
246 Previous Clinical Trials
5,073,332 Total Patients Enrolled
1 Trials studying Colitis
101 Patients Enrolled for Colitis
Sonia Michail, MDPrincipal InvestigatorChildren's Hospital Los Angeles
5 Previous Clinical Trials
144 Total Patients Enrolled
2 Trials studying Colitis
110 Patients Enrolled for Colitis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't had ulcerative colitis treatment in the last 4 weeks.I am between 7 and 21 years old with mild to moderate ulcerative colitis.I have had infectious colitis in the past.
Research Study Groups:
This trial has the following groups:- Group 1: open label intervention arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger